UnitedHealth: Why This Giant's Pain Might Pay Off

UnitedHealth Group reported Q2-FY25 revenue of $111.6 billion, up 12.9% YoY, but a $6.5 billion medical cost overrun sharply increased its Medical Care Ratio to 89.4% and prompted a cut in FY25 EPS outlook. Despite this, Medicare Advantage enrollment grew by 650,000 members, and the company projects FY25 revenue of $445.5–$448 billion with $16 billion in operating cash flow for shareholder returns. UNH stock is down 53% YTD, trading at a P/S of ~0.48, significantly below the sector median, indicating potential deep value despite underperformance linked to Medicare Advantage pricing and utilization issues.

Analysis

UnitedHealth Group (UNH) reported a conflicting second quarter for FY25, characterized by strong top-line growth but severe margin pressure. Revenue grew a robust 12.9% year-over-year to $111.6 billion, driven by strength in both its UnitedHealthcare and Optum divisions. However, this was significantly overshadowed by a $6.5 billion medical cost overrun, which caused the Medical Care Ratio (MCR) to spike to 89.4% and led management to cut its full-year FY25 EPS outlook. Despite these profitability challenges, stemming from structural weaknesses in Medicare Advantage (MA) pricing and utilization, the company demonstrated market leadership by adding 650,000 MA members. Looking ahead, UNH projects FY25 revenue between $445.5 and $448 billion and expects to generate a substantial $16 billion in operating cash flow, intended to fund buybacks and dividends. The market has reacted harshly to the cost issues, with the stock falling 53% year-to-date, resulting in a compressed valuation with a Price-to-Sales ratio of approximately 0.48, an 86% discount to the sector median, signaling a potential deep-value opportunity.

Key Decisions for Investors

• Given the stock's 53% year-to-date decline and a Price-to-Sales ratio of 0.48, value-oriented investors may find the current valuation a compelling entry point, contingent on the company's ability to stabilize costs.
• Investors should critically monitor the Medical Care Ratio in subsequent quarters, as a failure to control the cost overruns that pushed the MCR to 89.4% remains the primary risk to the investment thesis.
• The projected $16 billion in FY25 operating cash flow and continued growth in Medicare Advantage enrollment are key positive indicators to watch, as they provide a financial cushion and demonstrate underlying business strength that could support shareholder returns.